Navigation Links
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

r AP 12009 for recurrent or refractory anaplastic astrocytoma” (Poster Board No. 13, Abstract ID 2025), which will be on display from 08:00 a.m. to 12:00 p.m. on Sunday June 3rd 2007 in room (S 102a) on Level 1 of McCormick Place South Building.

The potential of AP 12009 as monotherapy in anaplastic astrocytoma patients will be further investigated in an international Phase III clinical trial currently in preparation, which is planned to include study centers in Europe, Asia, and North America.

For further information please contact:

ANTISENSE PHARMA GmbH

Dr. Heike Specht / Public Relations
Josef-Engert-Str. 9, D-93053 Regensburg
Phone: +49-941-92013-0
Fax: +49-941-92013-29
e-mail: pr@antisense-pharma.com
www.antisense-pharma.com

About ASCO

The American Society of Clinical Oncology (ASCO) Annual Meeting is a premier educational and scientific event, that brings together thousands of researchers and oncology professionals from all over the world.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.

The agents specifically block the synthesis of key cancer proteins. The lead product AP 12009 - a Transforming Growth Factor-beta2 inhibitor - is in advanced clinical development for the treatment of high-grade glioma as well as in Phase I/II clinical trial for the treatment of colorectal carcinoma, pancreatic carcinoma, and malignant melanoma. The further product pipeline covers preclinical drug candidates as well as co
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
5. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
6. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
9. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
Post Your Comments:
(Date:11/27/2008)...w study finds the majority of acute lymphoblastic ...resent at the time of diagnosis , , MEMPHIS...ists at St. Jude Children,s Research Hospital have...cer cells of children with acute lymphoblastic leu... a pathway to designing treatments for ALL relapse...
(Date:11/25/2008)...mptom awareness can improve recovery , , Au...y are available on the Mayo Clinic News Blog. Plea... , , ROCHESTER, Minn., Nov. 25 /PRNewswire...ty of stroke patients don,t think they,re having a...ent until their condition worsens. The findings ap...
(Date:11/25/2008)...UTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-Fir... PARD ), a biopharmaceutical company focused on,...at it will be exploring,strategic alternatives fo...low,the Company to focus its resources on the cli... candidate, and to support the initial commerciali...
(Date:11/24/2008)...ERFIELD, Ill., and OSAKA, Japan, Nov. 24 /PRNewswi...ts wholly-owned subsidiary, Takeda Global Research...oday that the Arthritis Advisory Committee of the ...d that the FDA approve febuxostat for the treatme...e was 12 to zero in favor of approval, with one pa...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3TVA fertilizer technology used worldwide but few new products since 1970s 4597 1TVA fertilizer technology used worldwide but few new products since 1970s 4597 2TVA fertilizer technology used worldwide but few new products since 1970s 4597 3TVA fertilizer technology used worldwide but few new products since 1970s 4597 4Alcohol consumption can cause too much cell death fetal abnormalities 4594 1Alcohol consumption can cause too much cell death fetal abnormalities 4594 2CSL Behrings Innovative HeliTrax 28SM 29 System Helps Physicians Manage Hemophilia A Patients 7302 1CSL Behrings Innovative HeliTrax 28SM 29 System Helps Physicians Manage Hemophilia A Patients 7302 2CSL Behrings Innovative HeliTrax 28SM 29 System Helps Physicians Manage Hemophilia A Patients 7302 3CSL Behrings Innovative HeliTrax 28SM 29 System Helps Physicians Manage Hemophilia A Patients 7302 4VioQuest Pharmaceuticals Inc Q2 08 Review Issued by Scimitar Equity LLC 7299 1VioQuest Pharmaceuticals Inc Q2 08 Review Issued by Scimitar Equity LLC 7299 2
...iety for Investigative,Dermatology, FREEPORT, N.Y....tics today announced new clinical research that th...d in liposomes,enhances DNA repair and reduces MMP...data was presented at the 68th Annual,Meeting of t...12,in Los Angeles, CA. , "Our clinical study sugg...
...ty for Investigative Dermatology, FREEPORT, N.Y., ...y announced new comparative clinical data that ind...recognize, transport and,utilize L-ergothioneine (...importantly, that (EGT) acts as a more powerful an... reactive oxygen,species and reducing UV-induced h...
Other Medicine Technology:AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells 2AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage 2
(Date:12/2/2008)... Orion Health announces that the SouthE...Juneau, Alaska, has selected the Rhapsody™ I... health record, radiology, pharmacy, laboratory an...t also plans to extend connectivity to statewide s...zation registry) and AKAIMS (an MIS and clinical d...
(Date:12/2/2008)... Liberty Mutual Provides Online Resourc...eSmart.com , Boston, MA ...nce and Holly Robinson Peete , actress, philanth...rage families to set aside a few moments before th...nd response plans at BeFireSmart.com. , , , , ,Ho...
(Date:12/2/2008)...c. 2 Population Service...sive project that could dramatically reduce the nu...aria. The program will provide free artemisinin-ba...munity health workers to poor children suspected o...treatment will be monitored to determine if it red...
(Date:12/1/2008)...d., Dec. 2 Patient satisfaction sc...the rise according to a new report,from Press Gan...ort: Patient,Perspectives on American Health Care...a driver for improvement in patient services. The...on patients treated at more than,1,200 outpatient...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 2Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 4Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever 2
...orpyrifos-an insecticide, while in their mother’s ...or development by three years of age and also have...vation was made in a peer-reviewed study conducted...fos, which was banned for residential use in 2001,...
... second opinion is very vital for cancer patients ...nd it should surely be taken before undergoing// s...Cancer Center wanted to find out whether cancer di...pecialists. The records of 149 breast cancer patie...
...ce that can be inserted inside the lungs with the ...can help treat asthma, researchers conducting its/...espiratory system in which the airways constrict m...t its worst, asthma can be fatal. Though asthma c...
...aves of the University of Minnesota School of Publ...ents on a daily basis tend to have a healthier// l...ecember Journal of American Dietetic Association w...0 US high school seniors. They were analyzed for h...
Other Medicine News:Health News:Chlorpyrifos Affects Mental Development of Foetus 2Health News:Cancer? Get A Second Opinion 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: